IMVT
Price
$15.66
Change
-$0.28 (-1.76%)
Updated
Jun 13 closing price
Capitalization
2.68B
51 days until earnings call
INCY
Price
$67.75
Change
-$1.47 (-2.12%)
Updated
Jun 13 closing price
Capitalization
13.11B
50 days until earnings call
Interact to see
Advertisement

IMVT vs INCY

Header iconIMVT vs INCY Comparison
Open Charts IMVT vs INCYBanner chart's image
Immunovant
Price$15.66
Change-$0.28 (-1.76%)
Volume$1.09M
Capitalization2.68B
Incyte
Price$67.75
Change-$1.47 (-2.12%)
Volume$1.83M
Capitalization13.11B
IMVT vs INCY Comparison Chart
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. INCY commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and INCY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (IMVT: $15.66 vs. INCY: $67.75)
Brand notoriety: IMVT: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 76% vs. INCY: 93%
Market capitalization -- IMVT: $2.68B vs. INCY: $13.11B
IMVT [@Biotechnology] is valued at $2.68B. INCY’s [@Biotechnology] market capitalization is $13.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • INCY’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 5 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s).

  • IMVT’s TA Score: 5 bullish, 4 bearish.
  • INCY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than INCY.

Price Growth

IMVT (@Biotechnology) experienced а -6.62% price change this week, while INCY (@Biotechnology) price change was -1.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

IMVT is expected to report earnings on Aug 06, 2025.

INCY is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($13.1B) has a higher market cap than IMVT($2.68B). INCY YTD gains are higher at: -1.911 vs. IMVT (-36.778). INCY has higher annual earnings (EBITDA): 407M vs. IMVT (-437.78M). INCY has more cash in the bank: 2.41B vs. IMVT (714M). IMVT has less debt than INCY: IMVT (98K) vs INCY (43.1M). INCY has higher revenues than IMVT: INCY (4.41B) vs IMVT (0).
IMVTINCYIMVT / INCY
Capitalization2.68B13.1B20%
EBITDA-437.78M407M-108%
Gain YTD-36.778-1.9111,924%
P/E RatioN/A338.75-
Revenue04.41B-
Total Cash714M2.41B30%
Total Debt98K43.1M0%
FUNDAMENTALS RATINGS
IMVT vs INCY: Fundamental Ratings
IMVT
INCY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9789
PRICE GROWTH RATING
1..100
6449
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (44) in the null industry is somewhat better than the same rating for INCY (93) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than INCY’s over the last 12 months.

IMVT's Profit vs Risk Rating (100) in the null industry is in the same range as INCY (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to INCY’s over the last 12 months.

INCY's SMR Rating (89) in the Biotechnology industry is in the same range as IMVT (97) in the null industry. This means that INCY’s stock grew similarly to IMVT’s over the last 12 months.

INCY's Price Growth Rating (49) in the Biotechnology industry is in the same range as IMVT (64) in the null industry. This means that INCY’s stock grew similarly to IMVT’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that INCY’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTINCY
RSI
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
58%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
61%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
58%
Advances
ODDS (%)
Bullish Trend 27 days ago
77%
Bullish Trend 6 days ago
60%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 25 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
64%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
YANG32.811.70
+5.46%
Direxion Daily FTSE China Bear 3X ETF
LDP20.60-0.08
-0.39%
Cohen & Steers Limited
IVVM32.04-0.15
-0.47%
iShares Large Cap Moderate Buffer ETF
KSPY26.07-0.12
-0.47%
KraneShares Hedgeye Hedged Eq Idx ETF
IYH56.90-0.35
-0.61%
iShares US Healthcare ETF

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.76%
ROIV - IMVT
62%
Loosely correlated
-1.31%
OCUL - IMVT
52%
Loosely correlated
-2.46%
DNLI - IMVT
52%
Loosely correlated
-2.51%
CGON - IMVT
52%
Loosely correlated
-2.42%
IDYA - IMVT
52%
Loosely correlated
-0.45%
More

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with REGN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then REGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-2.12%
REGN - INCY
40%
Loosely correlated
+1.42%
TECH - INCY
39%
Loosely correlated
-1.96%
RPRX - INCY
37%
Loosely correlated
-1.22%
IMVT - INCY
35%
Loosely correlated
-1.76%
KRYS - INCY
35%
Loosely correlated
-2.32%
More